Business Context and Reporting Period
This Form 8-K is a current report filed by Anthem, Inc. (now Elevance Health, Inc.) on September 16, 2019. The filing serves as a Regulation FD disclosure regarding upcoming investor meetings scheduled between September 16, 2019, and September 30, 2019.
Key Financial Metrics
The filing does not provide historical revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on forward-looking earnings guidance for the full year 2019.
- Full Year 2019 Net Income Guidance: Greater than $18.34 per share.
- Unfavorable Items: Approximately $0.96 per share included in the net income guidance.
- Adjusted Net Income Guidance: Greater than $19.30 per share (excluding the unfavorable items).
Material Changes
The filing states that the guidance reaffirmed does not include any adjustment items beyond those reported in the Company's second quarter 2019 earnings release. No specific material changes to financial position or operations are detailed in this document.
Guidance, Outlook, and Risks
Management intends to reaffirm the 2019 earnings guidance during investor meetings. The document includes extensive forward-looking statements subject to significant risks and uncertainties, including:
- Regulatory changes to the Affordable Care Act (ACA) and legal challenges thereto.
- Trends in healthcare costs, utilization rates, and premium rate approvals.
- Competitive pressures and enrollment reductions.
- Outcomes of litigation with Cigna Corporation regarding the terminated merger agreement.
- Compliance risks with pharmacy benefit management agreements (Express Scripts and CVS Health).
- Impact of data breaches, CMS Star ratings, and substantial outstanding indebtedness.
Investor Verification Checklist
- Verify the specific nature and magnitude of the $0.96 per share in "net unfavorable items" referenced in the Q2 2019 earnings release.
- Monitor the status and potential financial impact of the ongoing litigation with Cigna Corporation.
- Review updates on regulatory approvals for premium rates and changes to ACA implementation.
- Assess the transition status of pharmacy benefit management services from Express Scripts to CVS Health.